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Abstract
After initial response to androgen receptor targeting drugs abiraterone or enzalutamide, most 
patients develop progressive disease and therefore, castration resistant prostate cancer (CRPC) 
remains a terminal disease. Multiple mechanisms underlying acquired resistance have been 
postulated. Intratumoral androgen synthesis may resume after abiraterone treatment. A point 
mutation in the ligand binding domain of androgen receptor may confer resistance to 
enzalutamide. Emergence of androgen receptor splice variants lacking the ligand binding domain 
may mediate resistance to abiraterone and enzalutamide. Steroid receptors such as glucocorticoid 
receptor may substitute for androgen receptor. Drugs with novel mechanisms of action or 
combination therapy, along with biomarkers for patient selection, may be needed to improve the 
therapy of CRPC.
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Introduction
In the United States and Europe, prostate cancer has the highest incidence of malignancy 
and is the second or third leading cause of cancer-related death in men [1,2]. Dr. Charles 
Huggins demonstrated that androgen deprivation therapy (ADT) through surgical castration 
led to dramatic palliation of symptoms of metastatic prostate cancer and this seminal 
discovery ushered a new era of treatment in the 1940's [3]. These treatment principles were 
furthered cemented by Dr. Andrew Schally, who discovered the structure of luteinizing 
hormone-releasing hormone (LH-RH) [4]. This work led to development of LH-RH agonists 
in the 1980's. These agents and newer LH-RH antagonists are still the mainstay of advanced 
prostate cancer treatment. Unfortunately, virtually all patients develop castrate resistant 
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prostate cancer (CRPC) while on ADT. Metastatic CRPC (mCRPC) remains a terminal 
disease, and until recently, available treatment options of cytotoxic chemotherapy such as 
mitoxantrone or docetaxel. Mitoxantrone was approved in 1996 for its benefit in quality of 
life and bone pain without increasing survival. Doxetaxel was approved in 2004 based on 
two large randomized phase III trials. The TAX 327 study by Tannock et al demonstrated a 
2.9 month survival benefit and improvement in pain for mCRPC patients treated with 
docetaxel every 3 weeks and prednisone versus mitoxantrone and prednisone in the final 
analysis [5]. Similarly, the SWOG-9916 trial by Petrylak et al showed a 1.9 month survival 
benefit for mCRPC patient treated with docetaxel and estramustine versus mitoxantrone and 
prednisone [6]. In 2010, sipuleucel-T and cabazitaxel were approved for mCRPC. For 
asymptomatic or minimally symptomatic mCRPC patients, sipuleucel-T (which consists of 
autologous peripheral-blood mononuclear cells activated ex vivo with a prostatic acid 
phosphatase-granulocyte macrophage colony stimulating factor recombinant fusion protein 
and subsequent infusion of the cells into the patient) was approved on the basis of a clinical 
trial demonstrating a 4.1 month survival advantage (25.8 months vs 21.7 months) [7]. The 
semi-synthetic taxane-derivative cabazitaxel was shown to prolong survival by 2.4 months 
compared to mitoxantrone (15.1 months vs 12.7 months) in mCRPC patients who had 
progressed after docetaxel treatment [8]. The most recently approved agent is the α-emitting 
radiopharmaceutical Radium-223 chloride for use in mCRPC patients with symptomatic 
bone metastases and no visceral metastasis [9].
Previously, the role of the androgen receptor (AR) in progression to CRPC was less well 
appreciated and hence, disease progressing on ADT was termed “androgen-independent”, 
and this generated controversies on the necessity of continuing LH-RH agents. However, the 
recent development of two novel AR targeting drugs, abiraterone acetate (an oral androgen 
biosynthesis inhibitor) and enzalutamide (an oral antagonist of androgen receptor) provided 
firm evidence that the AR signaling axis remains an important driver of CRPC tumor 
progression. Despite meaningful clinical benefit of these agents, most patients will 
eventually succumb to CRPC because of acquired resistance to these drugs. This review 
article will highlight the potential mechanisms of resistance to androgen receptor targeting 
drugs and their implications for continued drug development in prostate cancer.
Androgen receptor and prostate cancer
The human AR gene is located on chromosome Xq11-12. AR consists of an N-terminal 
transactivation domain (encoded in exon 1), a DNA binding domain (DBD) (exon 2-3), a 
hinge region (exon 4), and a C-terminal ligand-binding domain (exon 5-8)(Figure 1A)[10]. 
5α-dihydrotestosterone (DHT), converted from testosterone by 5α-reductase, is the most 
potent ligand for AR. In the absence of ligand, AR is located in the cytoplasm in an inactive 
conformation bound by chaperone proteins such as heat shock proteins. Binding of androgen 
ligands to the ligand-binding domain of AR results in the translocation of AR from the 
cytoplasm to the nucleus. In the nucleus, AR binds androgen-response element DNA 
sequences located in the regulatory regions of its target genes, such as prostate specific 
antigen (PSA), and regulates their transcription. Prostate tumor cells are dependent on 
continued activation of AR for viability and proliferation. When gonadal testosterone 
production is inhibited by initiation of ADT and serum testosterone decreases to the castrate 
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level, AR without ligand is no longer bound to the DNA and loses its transcriptional activity 
in tumor cells. ADT is initially effective in palliating cancer-related symptoms such as bone 
pain and is associated with tumor regression. However, efficacy of ADT is short-lived. 
Patients with metastatic prostate cancer treated with ADT develop progressive disease after 
an average of approximately 24 months. This stage of disease, termed CRPC, is initially 
marked by rising levels of prostate specific antigen (PSA) as a harbinger of worsening 
symptoms and eventual death. Extensive evidence now supports the principle that 
reactivation of AR signaling drives CRPC progression. Multiple mechanisms underlying 
continued activation of AR in CRPC tumors include AR gene amplification, increased AR 
expression, AR point mutations, expression of AR splice variants, and intratumoral 
production of androgen [11]. Overexpression of AR, frequently due to genomic 
amplification of the AR gene, enhances transcriptional activation of AR to low levels of 
androgen in the castrate host [12]. In addition, CRPC tumors were found to contain 
unexpectedly high levels of testosterone and DHT and overexpress enzymes involved in 
androgen biosynthetic pathway [13,14]. Cytochrome P450 17A1 (CYP17A1) is a key 
enzyme in androgen synthesis via its 17α-hydroxylase/C17, 20-lyase activity. CYP17A1 
catalyzes the conversion of pregnenolone to 17-hydroxypregnenolone, then to the main 
androgen precursor dehydroepiandrosterone (DHEA). Although DHEA and its subsequent 
metabolite androstenedione are considered weak androgens, they play an important role in 
intratumoral synthesis of androgens in CRPC.
Clinical efficacy of new-generation AR targeting drugs
Abiraterone acetate
Abiraterone is a potent and specific inhibitor of CYP17A1 [15]. Inhibition of CYP17A1 
should decrease adrenal and intratumoral androgen production and thereby reduce the 
availability of androgen ligands for AR in tumor cells. Based on the results of a phase III 
clinical trial, FDA approved abiraterone plus prednisone in April, 2011, for treatment of 
CRPC patients who received prior docetaxel chemotherapy. Prednisone is added to 
abiraterone in an attempt to minimize the production of the excess mineralicorticoid 
hormones that may result from CYP17 inhibition. The COU-AA-301 trial randomized 1,195 
CRPC patients in a 2:1 ratio to either 1,000 mg of abiraterone plus prednisone 5 mg twice 
daily or placebo plus prednisone [16]. After a median follow-up of 12.8 months, the 
abiraterone plus prednisone group had a longer OS of 14.8 months vs 10.9 months for 
placebo (hazard ratio (HR) of 0.65). The abiraterone plus prednisone group was also favored 
for secondary outcome measures, including time to PSA progression (10.2 vs 6.6 months), 
progression free survival (5.6 months vs 3.6 months), and PSA response rate (29% vs. 6%). 
Adverse events that were associated with higher mineralocorticoid levels due to CYP17 
blockage such as fluid retention, edema, hypokalemia, and hypertension were more common 
in the abiraterone plus prednisone group (55% vs 43%). Final analysis of the study 
confirmed the OS benefit for the abiraterone plus prednisone group (15.8 months vs 11.2 
months; HR of 0.74) [17]. Results of COU-AA-301 provided an fundamentally important 
insight by demonstrating that AR targeting is an effective strategy in the most advanced 
stage of prostate cancer that progressed after chemotherapy.
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The COU-AA-302 phase III randomized trial focused treatment of mCRPC in patients who 
have not yet received docetaxel chemotherapy. In this study, 1,088 patients were 
randomized to receive abiraterone plus prednisone or placebo plus prednisone with the two 
primary endpoints: OS and radiographic PFS. With a median follow-up of 22.2 months, 
there was a strong trend toward improved OS with abiraterone (median not reached vs 27.2 
months for placebo plus prednisone; HR, 0.75) as well as improvement in radiographic PFS 
(16.5 months for abiraterone vs. 8.3 months with placebo; HR, 0.53) [18]. Pre-specified 
secondary and exploratory efficacy endpoints, including risk of decline in performance-
status (12.3 vs 10.9 months; HR, 0.82), median time to the initiation of cytotoxic 
chemotherapy (25.2 months vs. 16.8 months; HR, 0.58), a significant delay in the time to 
opiate use for cancer-related pain (not reached vs. 23.7 months; HR, 0.69) and median time 
to PSA progression (11.1 months vs. 5.6 months; HR 0.49,) favored the abiraterone group. 
Based on these results, abiraterone plus prednisone received FDA approval in December 
2012 for treatment of mCRPC in the pre-chemotherapy setting. In addition, Basch et al 
reported that in this trial, the abiraterone group had a delay in patient-reported pain 
progression (26.7 months vs 18.4 months; HR, 0.82) and health-related quality of life 
deterioration (12.7 months vs 8.3 months; HR, 0.78) [19]. Abiraterone has become widely 
accepted as a treatment for CRPC with a favorable efficacy/toxicity profile.
Enzalutamide
First-generation antiandrogens such as flutamide and bicalutamide are antagonists of AR 
binding to ligands and inhibit AR activity. However, their clinical activity as a treatment of 
CRPC is modest and transient. At the molecular level, first-generation antiandrogens may 
act to stimulate AR activity in CRPC tumor cells that overexpress AR rather than antagonize 
AR [12]. Enzalutamide (also known as MDV3100) was designed to be a more potent 
antagonist of AR without agonist effects in tumor cells that overexpress AR [20]. Scher et al 
studied enzalutamide in a phase III placebo-controlled trial called AFFIRM [21]. 1,199 men 
with mCRPC progressing after chemotherapy were randomly assigned in a 2:1 ratio to 
receive oral enzalutamide at a dose of 160 mg per day or placebo. The primary endpoint was 
OS. The enzalutamide group showed a median OS of 18.4 months versus 13.6 months in the 
placebo group (HR, 0.63). Enzalutamide was favored over placebo with other secondary end 
points, including the PSA response rate (54 vs. 2%), time to PSA progression (8.3 months 
vs. 3 months; HR, 0.25), radiographic PFS (8.3 months vs. 2.9 months; HR, 0.40), and time 
to the first skeletal-related event (16.7 months vs. 13.3 months; HR). Side-effects including 
fatigue, diarrhea, hot flashes, and rarely seizures (0.6%) were noted in the enzalutamide 
groups. Based on the results of this trial, enzalutamide received FDA approval in August, 
2012 as a second line treatment for mCRPC after docetaxel-based chemotherapy. Results 
from a phase III trial called the PREVAIL study (NCT01212991) that investigated the 
efficacy of enzalutamide in chemotherapy-naïve patients with mCRPC were recently 
reported in an abstract [22]. After randomizing 1,717 men, an interim analysis after 539 
deaths demonstrated that in the enzalutamide group, there was a 30% reduction in the risk of 
death with the median OS of 32.4 months vs 30.2 months in the placebo group. For the other 
co-primary endpoint, the enzalutamide group also showed an 81% reduction in risk of 
radiographic progression or death. These studies demonstrating clinical efficacy of 
enzalutamide further highlight the pivotal role AR-signaling pathway plays in CRPC.
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Potential Mechanisms of Acquired Drug Resistance
Abiraterone and enzalutamide represent a paradigm shift in our approach to CRPC treatment 
by refocusing on AR as the critical therapeutic target in CRPC. However, most patients 
treated with these agents will die from their disease and prolongation of survival by only a 
few months in the post-chemotherapy setting represents a modest improvement. 
Understanding the mechanisms involved in progression of tumor after initially responding to 
drug treatment is necessary for improvement in therapy outcome. Studies of preclinical 
models as well as analysis of primary tumor specimens have yielded valuable insights into 
the tumor biology of CRPC that led to development of new agents and will likely be 
important in characterizing the nature of acquired resistance to novel AR targeting agents. In 
clinical trials of abiraterone and enzalutamide, progression of CRPC is accompanied by the 
rise in PSA in most patients and this observation suggests that mechanisms of acquired 
resistance to these agents may predominantly involve reactivation of androgen signaling 
pathways since PSA expression is driven by AR. Potential mechanisms derived from 
preclinical studies and emerging from clinical specimens will be reviewed (Table 1).
Intratumoral androgen synthesis
Abiraterone treatment results in marked reduction in testosterone and DHT levels in blood 
and tumor-infiltrated bone marrow aspirates of CRPC patients [23]. This finding supports 
the concept that the clinical efficacy of abiraterone derives from inhibition of intratumoral 
production of androgen. In CRPC xenograft tumors, abiraterone treatment reduced 
testosterone and DHT levels in tumor tissues [24]. CYP17 inhibition (by abiraterone or by 
ketoconazole, a less potent inhibitor) leads to increased expression of CYP17A1 transcripts 
and other transcripts encoding enzymes involved in steroid synthesis in tumor cells [24,25]. 
These results suggest that CYP17 inhibition may select for tumor cells that reactivate the 
androgen synthesis pathway and thereby become resistant to abiraterone. However, in one of 
two xenograft models, androgen levels in abiraterone-resistant tumors remained suppressed 
[24] and this suggests alternate mechanisms of resistance to abiraterone, as detailed in 
subsequent sections. There may be multiple pathways for CRPC tumors to produce DHT. 
3β-hydroxysteroid dehydrogenase 1 (3βHSD1) is involved in synthesis of DHT from adrenal 
androgen DHEA and may allow increased accumulation of DHT in tumor tissue in a 
synthetic pathway that bypasses testosterone. A gain-of-function point mutation in 3βHSD1 
was found to be associated with CRPC [26]. Development of abiraterone resistance in 
xenograft tumors was associated with acquisition of this mutation. This suggests the 
possibility that CRPC tumors may synthesize DHT through alternate pathways in the setting 
of continuing CYP17 inhibition by abiraterone. Several plausible alterations in intratumoral 
steroid metabolism that may lead to abiraterone resistance have been suggested by 
preclinical models. More extensive studies of tumor specimens collected from patients 
treated with abiraterone will be required to determine if any of proposed mechanisms 
contributes to clinical resistance to abiraterone.
AR structural alterations: point mutations
One of the most frequent genomic alterations in CRPC is high level gene amplification of 
AR found in ∼30% of CRPC tumors[27]. AR gene amplification is rarely found in tumors 
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prior to ADT. Increased AR expression resulting from high copy numbers of the AR gene 
leads to constitutive activation of AR in the castrate environment and resistance to first-
generation antiandrogens such as bicalutamide[12]. The AR gene may acquire a gain-of-
function point mutation in prostate tumor cells [28], as opposed to loss of function mutations 
associated with congenital androgen insensitivity syndrome. The AR point mutation usually 
affects the ligand binding domain and broadens the specificity of ligands that are capable of 
activating the receptor. Mutant AR may respond to adrenal androgens and steroid hormones 
such as corticosteroids, progesterone, estrogens, and even antiandrogens as agonists. 
10-20% of CRPC tumors may have a mutation in AR and it is most frequently found in 
CRPC tumors exposed to ADT and antiandrogen for a prolonged period [29]. This data 
suggests that AR mutations develop under a strong selective pressure of antiandrogen use. 
Since enzalutamide acts as a competitive inhibitor of binding between AR and DHT [20], 
one may postulate that a point mutation in the critical residue on the AR protein that 
mediates binding to enzalutamide would confer resistance to enzalutamide. Balbas et al 
performed mutagenesis screen for AR resistant to enzalutamide and found the AR mutation 
in which phenylalanine at amino acid 876, located in the ligand binding domain, is 
substituted with leucine (referred to as F876L mutation) [30]. This F876L mutation 
converted enzalutamide into an agonist and expression of the AR F876L mutant in prostate 
cancer cells led to resistance to growth inhibition by enzalutamide. This mutant also 
conferred resistance to ARN-509, a novel potent AR antagonist in clinical development 
[31]. Two independent studies also identified the F876L mutation by deriving prostate 
cancer cell lines that became resistant to enzalutamide or ARN-509 [32,33]. The AR F876L 
mutant encoding DNA (presumably associated with circulating tumor cells shed from 
prostate cancer) was detected in the plasma of patients with progressive disease on 
ARN-509 treatment, but not in pre-treatment specimens [32]. This finding is consistent with 
the hypothesis that acquired resistance to enzalutamide or ARN-509 is mediated by 
emergence of AR F876L mutation. Point mutations in many codons in the ligand binding 
domain of AR are associated with development of resistance to first-generation 
antiandrogens[29]. It is unclear presently whether there are additional residues in AR protein 
that could be mutated to confer resistance to second-generation antiandrogens. If the F876L 
mutation is the only target of mutation for resistance, the development of mutation may be 
expected to be less frequent than it would be the case if multiple residues could be altered 
for resistance. Also, the spectrum of mutations leading to resistance would have implications 
for designing new generations of antiandrogens and strategies for overcoming or preventing 
resistance.
AR structural alterations: splice variants lacking the ligand binding domain
Several groups independently characterized the occurrence of splice variants of AR initially 
in prostate cancer cell lines and xenograft tumors and in clinical specimens [34-37]. More 
than 11 isoforms of AR have been characterized [38] and most of splice variants share the 
common structural motifs of the N-terminal transactivation domain and the central DNA 
binding domain. However, these truncated AR splice variants lack the ligand binding 
domain. AR splice variant AR-V7 (also named AR3) contains exon 1 (encoding the N-
terminal transactivation domain), exon 2-3 (encoding the DNA binding domain), and a 
terminal cryptic exon (Figure 1B)[35,36]. Other AR splice variants typically contain exon 
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1-3, but differ in the terminal cryptic exons [38]. Another major variant, ARv567es (exons 
skipped), contains exons 1–4 and because of a frame-shift from loss of exons 5–7, exon 8 
has a stop codon generated resulting in truncated AR protein lacking the ligand binding 
domain[37]. Investigators, by using a PCR assay for the mRNA or an antibody directed 
against the unique C-terminal peptide of the AR-V7/AR3, demonstrated that expression of 
AR variants in clinical specimens increased with progression to CRPC and increased 
expression correlated with the risk of recurrence of cancer after prostatectomy or shortened 
survival of CRPC patients [35,36,39]. AR splice variants, since they do not contain the 
ligand-binding domain, are constitutively active without the need for ligands. They are 
constitutively localized to the nucleus and activate AR target gene expression in the 
androgen depleted environment [40,41]. The AR splice variants induce a distinct set of 
genes associated with the cell cycle while full length AR activation is associated with genes 
involved in biosynthesis, metabolism and differentiation [41]. Truncated AR splice variant 
proteins interact with and activates full length AR protein in an androgen-independent 
manner [37,42]. AR splice variant proteins also interact with other transcription factors and 
coactivators such as FOXO1, NF-κB2/p52, and Vav3, and these interactions regulate the 
functional activity of AR splice variants through multiple signaling pathways [43-45]. In 
preclinical models, expression of AR splice variants promotes castration resistant growth of 
xenograft tumors [35]. Since the activity of AR splice variants is not expected to be 
inhibited by abiraterone and enzalutamide, one may hypothesize that treatment with 
abiraterone or enzalutamide would select for tumor cells that express AR splice variants and 
thereby reactivate AR target genes and resume growth. In xenograft models, treatment with 
abiraterone and enzalutamide induced the expression of AR variants AR-V7 and ARv567es 
[24,41]. Mechanisms underlying a shift to expression of AR splice variants were suggested 
by the finding of genomic rearrangement (focal deletion or duplication) within the AR gene 
locus that occurs in cell lines and in primary CPRC tumors [46-48]. In the heterogeneous 
cell population with cells containing intact or rearranged AR gene locus, androgen 
deprivation selected for clones containing AR gene rearrangement and increased expression 
of truncated AR variants [46]. Cells with the rearranged AR gene locus were resistant to 
enzalutamide [47]. In many tumor types, gene amplification and rearrangement occur 
together, presumably due to common underlying mechanisms. Therefore, the potential 
hypothesis is that in prostate cancer cells, gene amplification and rearrangement in the AR 
locus may be selected during tumor evolution as a result of selective pressure put on by 
androgen deprivation, then antiandrogen treatment. Emergence of truncated AR splice 
variants will allow continued growth of prostate cancer cells that require expression of AR 
target genes. Recent characterization of the prostate cancer genome demonstrated that there 
are extensive genomic rearrangement and translocations in a process termed “chromoplexy” 
[49]. However, expression of AR splice variants from genomic rearrangement has not been 
confirmed in clinical specimens yet and the extent to which AR splice variants and AR gene 
rearrangement contribute to clinical resistance to abiraterone and enzalutamide remains to be 
characterized.
Glucocorticoid receptor that may bypass AR
New data suggests that glucocorticoid receptor (GR)-mediated expression of a subset of AR 
target genes in the presence of AR inhibition by potent antiandrogen therapy is an alternate 
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mechanism of resistance [50]. Gene expression analysis of harvested tumors resistant to 
antiandrogen treatment demonstrated high GR expression. Moreover, cells derived from 
enzalutamide-resistant xenografts require GR expression for enzalutamide-resistant tumor 
growth. Furthermore, GR has the ability to drive expression of a subset of AR target genes 
in enzalutamide-resistant cell lines. Elevated expression of GR in clinical specimens of 
mCRPC predicted for poor response to enzalutamide. Treatment of cells with 
dexamethasone (GR agonist) induced resistance to enzalutamide. Thus, the loss or inhibition 
of AR transcriptional activity could be bypassed by the expression of other steroid receptors 
that may activate a subset of AR target genes required for growth. These data raises a 
possibility that improving outcome of antiandrogen treatment may require combined 
inhibition of AR and GR. Indeed, the post-hoc analysis of the phase III AFFIRM trial of 
enzalutamide showing that patients with concomitant use of corticosteroids had worse 
outcome with enzalutamide is consistent with this hypothesis that GR may bypass the AR 
inhibition to drive prostate cancer progression, but confounding variables preclude definitive 
conclusions [51].
In summary, multiple independent mechanisms have been proposed after studies of 
preclinical models and there is emerging evidence supporting these mechanisms from 
clinical studies. However, the relative importance of each mechanism remains unclear at this 
time.
Novel AR targeting drugs in clinical development
Novel AR antagonists
Similar to enzalutamide, ARN-509 is a competitive AR inhibitor that fully antagonizes 
overexpressed AR without agonist activity. ARN-509 exhibited greater activity in 
preclinical models than bicalutamide and enzalutamide [31]. Rathkopf et al examined thirty 
patients with progressive mCRPC who received continuous oral doses between 30 mg and 
480 mg daily and were monitored by positron emission tomography/computed tomography 
(PET/CT) imaging for binding of [(18)F] fluoro-α -dihydrotestosterone (FDHT) to tumors 
before and during treatment [52]. PSA declines greater than 50% at 12 weeks was observed 
in 46.7% of patients. Reduction in FDHT uptake was observed at all doses with a plateau at 
120 mg or higher. Adverse events observed most frequently was fatigue (47%). Based on 
this overall safety of this study, phase II clinical trials using ARN-509 at 240 mg daily are in 
progress (NCT01171898). In addition, ARN-509 is being investigated in combination with 
abiraterone plus prednisone through a phase Ib study in mCRPC patients (NCT01792687). 
ODM-201 is another AR antagonist in early phase clinical development [53,54].
Novel CYP17 inhibitors
Similar to abiraterone, both galeterone (TOK-001, VN/124-1) and orteronel (TAK-700) are 
novel CYP17 inhibitors in clinical development for treatment of CRPC [55,56]. Galeterone 
disrupts the AR signaling in three ways: 1) Selec tivelyinhibiting C17, 20 lyase, 2) 
competitively antagonizing androgen binding to AR, and 3) degrading the AR protein itself 
[57]. When compared to both abiraterone and orteronel, galeterone was the most potent 
CYP17 inhibitor with minimal effects on 17α-hydroxylase products, which are responsible 
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for decrease in cortisol and negative feedback increase in ACTH, resulting in 
mineralcorticoid excess symptoms such as hypokalemia, hypertension, and edema seen with 
abiraterone. Galeterone would therefore not require concomitant prednisone administration. 
Currently, a phase II trial evaluating the safety and efficacy of galeterone in CRPC patients 
is underway (NCT01709734). Orteronel was less potent than galeterone or abiraterone, but 
more selective for CYP17A1 lyase inhibition with reduced hydroxylase products [58]. 
Several studies with orteronel are underway or have been completed. The phase III trial of 
post-docetaxel mCRPC patients assigned to orteronel plus prednisone vs placebo plus 
prednisone (NCT01193257) was recently reported as failing to meet its primary endpoint of 
prolonging overall survival (17.0 months vs 15.2 months; HR of 0.886; p=0.1898) [59]. A 
similarly designed phase III randomized trial with orteronel in chemotherapy-naïve mCRPC 
patients (NCT01193244) is awaiting completion. A phase II trial comparing orteronel vs 
bicalutamide in patients with metastatic prostate cancer who failed first line treatment with 
LH-RH agonists (NCT01658527) is currently under way. A phase III randomized trial to 
compare ADT plus orteronel 300 mg twice daily versus ADT plus bicalutamide 50 mg daily 
in patients with newly diagnosed metastatic hormone sensitive prostate cancer 
(NCT01809691) is also ongoing.
Potential strategies for overcoming acquired resistance
Novel inhibitor of AR transactivation domain
Anderson et al identified EPI-001, a small molecule agent that blocks transactivation of the 
AR N-terminal domain and demonstrated that EPI-001 inhibited growth of CRPC xenograft 
tumors in animals [60]. EPI-001 and its structural analogs inhibit the AR transactivation by 
covalently binding to the N-terminal domain. EPI analogs blocked growth of CRPC 
xenograft tumors driven by AR splice variants lacking the ligand binding domain [61]. 
These preclinical data highlights the potential for novel compounds that target the AR 
function through mechanisms distinct from abiraterone and enzalutamide and thereby 
overcome resistance to these agents. Future clinical trials that target the AR N-terminal 
domain are warranted.
Combination therapy
The current practice of sequential monotherapy with targeted agents in diseases such as 
chronic myelogenous leukemia may lead to acquisition of multidrug resistance and 
therefore, combination therapy may delay disease progression. and improve clinical 
outcome [62]. Similarly, combination therapy with abiraterone and enzalutamide may 
suppress emergence of acquired resistance. A phase 3 trial is being planned to compare the 
overall survival of mCRPC patients treated with enzalutamide alone vs enzalutamide and 
abiraterone (NCT01949337). Other approaches may include adding agents with a non-cross 
resistant mechanism, such as combing AR targeted agents with Radium-223 or cabazatinib 
(an inhibitor of c-Met and vascular endothelial growth factor receptor 2 tyrosine kinases 
[63]).
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The approval of abiraterone and enzalutamide for treatment of CRPC represents a 
substantial progress. However, patients with CRPC still succumb to their disease within a 
few years because of acquired resistance to these agents. Preclinical and clinical data 
suggest that there are several potential mechanisms involved in development of resistance, 
such as intratumoral androgen synthesis, structural alterations in AR (i.e. point mutations 
and splice variants lacking the ligand binding domain), and other steroid hormone receptors 
that may bypass AR. The relative contribution of these mechanisms is unknown at present. 
Future drug development will need to address these resistance mechanisms in order to 
improve the clinical efficacy of novel agents in CRPC patients who have already been 
treated with abiraterone or enzalutamide.
Expert Commentary
Since 2010, five agents that have demonstrated an increased survival in phase III trials 
(sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, and Radium-223) have become 
available to clinicians for treatment of patients with mCRPC. The pace of progress has been 
unprecedented and these advances are fueled by improved understanding of tumor biology 
and signaling mechanisms. Before these agents, docetaxel chemotherapy represented the 
only agent known to increase survival and patients progressing after docetaxel had few 
treatment options and faced poor prognosis with survival less than 12 months. Therefore, 
drug development efforts and clinical trials initially focused on patients who already 
received docetaxel, in part due to the fact that survival endpoints are feasible with a 
relatively short follow up. In this setting, cabazitaxel, abiraterone, enzalutamide, and 
Radium-223 received US FDA approval for treatment of mCRPC. However, proliferation of 
active available agents raises difficult questions. Is there an optimal agent for an individual 
patient? Is there an optimal sequence of treatment? The patient's co-morbidities (such as 
heart failure or history of seizures) and preference would make an impact in some cases, but 
in many cases, there is no currently available evidence or biomarkers to help clinicians and 
patients make an informed choice. Because of the favorable toxicity profile and oral dosing, 
abiraterone and enzalutamide are appealing both in the post- and pre-chemotherapy settings. 
There is now emerging evidence for cross-resistance between abiraterone and enzalutamide. 
In patients who have previously taken abiraterone, enzalutamide treatment is only modestly 
active, with a lower PSA response rate and a shorter duration of response, than expected for 
those who have not received abiraterone [64,65]. In patients who have been exposed to 
enzalutamide, abiraterone is less active than in those who never took enzalutamide [66,67]. 
These results suggest common mechanisms of resistance to both of these agents, as 
discussed above. For example, emergence of AR splice variants without the ligand binding 
domain will lead to reactivation of AR signaling after abiraterone and enzalutamide 
treatment. AR point mutation may confer resistance to one or both drugs. Novel drugs in 
development may be able to address mechanisms of acquired drug resistance. In chronic 
myelogenous leukemia, the disease that ushered the era of targeted therapy in clinical 
oncology, more potent kinase inhibitors introduced after imatinib, the first Bcr-Abl kinase 
inhibitor, appear to produce more durable remission although resistance may eventually 
develop. It is not yet clear that novel agents such as ARN-509 or galeterone will be more 
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effective than abiraterone or enzalutamide. Further studies will be necessary. Combination 
therapy with both abiraterone and enzalutamide has the potential to improve the clinical 
efficacy relative to monotherapy. Novel drugs that inhibit the N-terminal transactivation of 
AR may inhibit tumors driven by AR splice variants that mediate resistance to abiraterone 
and enzalutamide. However, if glucorticoid receptor or another steroid hormone receptor or 
more broadly other pathways drive tumor escaping from complete AR inhibition, these 
mechanisms of resistance will likely require non-AR targeting drugs. Currently, biomarkers 
that distinguish between these alternative mechanisms are lacking.
Five-year view
Over next five years, clinical studies of next generation AR antagonists such as ARN-509 
and ODM-201 or novel CYP17 inhibitors such as galeterone and orteronel will be 
completed in an attempt to demonstrate clinical efficacy of these agents in a defined clinical 
setting (i.e. nonmetastatic CRPC or post-chemotherapy mCRPC). However, the survival 
endpoint, the “gold standard” of clinical efficacy in oncology, will be increasingly difficult 
to demonstrate, in part due to availability of multiple agents and increasing survival 
stemming from stage migration in which CRPC patients are treated earlier in the course of 
the disease. Given the fact that tumor cells may overcome drugs such as abiraterone and 
enzalutamide targeting the ligand bind domain of AR through several distinct mechanisms, 
it remains to be seen whether drugs currently in development with mechanisms similar to 
available agents (i.e. CYP17 inhibitors or AR antagonists) represent substantial 
improvement in treatment of mCRPC patients. It is likely that drugs targeting the N-terminal 
transactivation domain of AR will be developed. Clinical trials will explore the optimal 
sequencing and combinations of AR targeted agents. Biomarkers that may predict for 
response to novel therapy will likely contribute greatly to drug development. For example, 
detection of specific AR point mutants, analogous to Bcr-Abl mutants in chronic 
myelogenous leukemia, may help in selection of AR antagonists. Expression of AR splice 
variants or glucocorticoid receptor in tumor may be associated with resistance to certain 
agents or sensitivity to other agents. High throughput sequencing technology may be another 
avenue of biomarker development. It is likely that prognosis of patients with CRPC will 
continue to improve in the near future.
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• The recent approval of abiraterone (androgen synthesis inhibitor) and 
enzalutamide (androgen receptor antagonist), based on randomized clinical trials 
showing increased survival in pre-chemotherapy and post-chemotherapy 
mCRPC patients, establishes androgen receptor as an important therapeutic 
target in CRPC.
• After initial response, most patients develop progressive disease, with a rising 
PSA, the androgen receptor target gene. In many patients, there may be cross 
resistance to abiraterone and enzalutamide. Understanding mechanisms of 
resistance is necessary for developing better treatments.
• Resistance to abiraterone may include reactivation of intratumoral androgen 
synthesis through increased expression of CYP17 or other enzymes involved in 
androgen synthesis.
• A point mutation F867L in the ligand binding domain of androgen receptor 
confers resistance to second-generation antiandrogens enzalutamide and 
ARN-509.
• Emergence of androgen receptor splice variants lacking the ligand binding 
domain may mediate resistance to abiraterone or enzalutamide. Novel agents 
such as EPI-001 targeting the N-terminal transactivation domain of androgen 
receptor may be effective in inhibiting splice variants.
• Glucocorticoid receptor in tumor cells may bypass the need for androgen 
receptor by activating some androgen target genes.
• Combination therapy with existing or novel drugs may delay development of 
resistance.
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Schematic of androgen receptor and major splice variants. (A) Functional domains of full 
length androgen receptor protein. NTD=N-terminal transactivation domain, DBD=DNA 
binding domain, H=hinge region, LBD=ligand binding domain. (B) Organization of the 
mRNA species encoding androgen receptor and the major splice variants. Exons 1-8 or 
cryptic exon 3 contained in the transcript are indicated. Shaded areas represent untranslated 
regions. FL=full length, CE3=cryptic exon 3, V7=variant 7, v567es=variant 5, 6, 7 exons 
skipped. Data for AR-V7 is from ref. [36]. Data for AR3 is from ref. [35]. Data for 
ARv567es is from ref. [37].
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Table 1
Proposed mechanisms of acquired resistance to novel agents
Mechanism Reference
Increased intratumoral androgen production [24-26]
Androgen receptor point mutation F876L [30,32,33]
Androgen receptor splice variants [24,41,47]
Glucocorticoid receptor bypassing androgen receptor [50]
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